Subcutaneous pembrolizumab reduces time demands for both the patient and clinician, all while providing a consistent efficacy ...
The Print on MSN2d
PGIMER report bats for new-age targeted lung cancer therapies to be included in AB-PMJAYReport commissioned by govt analysed cost-effectiveness of 2 medicines, comparing them to to chemo in patients with newly ...
Cutaneous melanoma, the most aggressive form of skin cancer, is characterized by its accumulation of a large number of ...
BNT327 combined with chemotherapy showed an overall response rate of 85.4% when used as a first-line treatment for ...
BMS is already testing the combo against just Keytruda as a first-line treatment in a Phase III trial in KRAS G12C-mutant and ...
The following is a summary of "Mediastinal staging lymph node probability map in non-small cell lung cancer,” published in the March 2025 issue of Respiratory Research by Bordas-Martinez et al.
Merck’s new formulation of the mega-blockbuster Keytruda, made in collaboration with Alteogen, could help to keep the drug’s ...
Feb. 12, 2025 — Researchers have found that some particularly aggressive lung cancer cells can develop their own electric network, like that seen in the body's nervous ... Feb. 6, 2025 ...
Radiopharm Theranostics Limited targets oncology with radiotherapeutics like Lu-RAD204 for NSCLC. Key 2025 data signals ...
Merck has filed a petition with the U.S. Patent and Trademark Office to challenge seven of Halozyme’s patents. Halozyme said ...
The TKI zongertinib is currently being reviewed by the FDA for a potential approval for patients with HER2 mutation–positive ...
Molecular residual disease precedes DFS events in patients receiving osimertinib, placebo; most events occur after osimertinib discontinuation or completion.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback